尿C4d水平与IgA肾病疾病进展的关联
本研究纳入508例经活检证实的IgA肾病患者,基线尿C4d用ELISA定量,随访中位36个月,70例(13.8%)达到肾脏进展事件。
要点
- 尿C4d/Ucr升高与IgA肾病CKD进展风险独立相关,调整HR 1.46。
- 高C4d组较低C4d组肾脏不良结局风险调整HR 1.93。
- 低基线C4d与3个月免疫抑制治疗蛋白尿良好应答独立相关。
核心结论
- 尿C4d作为无创生物标志物与IgA肾病进展相关,并可能预测蛋白尿对免疫抑制治疗的应答。
研究设计与样本
- 纳入508例经活检证实的IgA肾病患者,收集活检时基线尿样,用ELISA定量尿C4d。
- 在序贯尿样中测定时间平均C4d(TA-C4d)和蛋白尿变化,中位随访36个月。
- 肾脏进展事件定义为eGFR下降50%或终末期肾病或死亡。
主要发现
- 随访期间70例(13.8%)达到肾脏进展事件。
- 尿C4d/Ucr较高与eGFR降低、大量蛋白尿、低血清白蛋白、高血压及严重Oxford E和T评分相关。
临床怎么用
- 尿C4d/Ucr或可作为IgA肾病无创风险分层工具,辅助识别CKD进展高风险患者。
- 基线尿C4d低者可能更易从免疫抑制治疗中获得蛋白尿应答,但需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: C4d mesangial deposition, a hallmark of lectin pathway activation in immunoglobulin A nephropathy (IgAN), has been shown to be associated with risk of kidney failure. To date, the relationship between urinary C4d and renal outcome remain unelucidated. METHODS: A total of 508 patients with biopsy-proven IgAN were enrolled in this study, whose baseline urine samples at the time of biopsy were collected and the levels of urinary C4d were quantified by enzyme-linked immunosorbent assay. The time-averaged C4d (TA-C4d) and the change in proteinuria were measured in sequential urine samples obtained from IgAN patients. The kidney progression event was defined as a 50% estimated glomerular filtration rate (eGFR) decline or end-stage kidney disease or death. RESULTS: After a median follow-up of 36 months, 70 (13.8%) of the participants reached the kidney progression event. Higher levels of urinary C4d/Ucr were found to be associated with decreased eGFR, massive proteinuria, lower serum albumin levels, hypertension, and severe Oxford E and T scores. Upon adjusting for traditional risk factors (including demographics, eGFR, proteinuria, hypertension, Oxford pathologic score and immunosuppressive therapy), elevated levels of urinary C4d/Ucr were independently associated with an increased risk of chronic kidney disease progression [adjusted hazard ratio (HR) per standard deviation increment of log-transformed C4d/Ucr: 1.46; 95% CI 1.04-2.06; P = .030]. In reference to the low C4d group, the risk of poor renal outcome increased for the high C4d group (adjusted HR 1.93; 95% CI 1.05-3.54; P = .033). Additionally, a low baseline C4d level was independently associated with a favorable proteinuria response to immunosuppressive therapy at 3 months (adjusted relative risk 2.20; 95% CI 1.04-4.63, P = .038). CONCLUSION: The urinary C4d, serving as a non-invasive biomarker, is associated with the progression of IgAN and holds the potential to predict proteinuria response in this disease.
引用
- Dong Y, Wang Z, Guo W, et al. Association between urinary C4d levels and disease progression in IgA nephropathy. Nephrol Dial Transplant. 2024. PMID: 38178632. doi:10.1093/ndt/gfae001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。